+1-206-701-6702
+44-020-8133-4027
+050-5539-1737
+91-848-285-0837
Press Release: Sexual Health Market to surpass US$ 14.1 Billion by 2027
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Physical or psychological factors both can result into sexual dysfunction. In most cases issues with sexual health result from a combination of physical and psychological factors. It is a common health problem in both men and women. Delayed ejaculation, premature ejaculation, and inability to achieve full erection are some common sexual dysfunction symptoms in men, while symptoms such as vaginal dryness, dyspareunia are observed in women. Sexual dysfunction is categorized into four main types including desire disorders, arousal disorders, orgasm disorders, and pain disorders. These conditions can be well treated with drugs such as erectile dysfunction drugs, gender dysphoria drugs, hypoactive sexual desire disorder drugs, and premature ejaculation drugs.
The global sexual health market is estimated to be valued at US$ 10,697.3 million in 2019, and is expected to exhibit a CAGR of 4.2% during the forecast period (2019–2027).
Figure 1. Global Sexual Health Market Share (%), By Product Type, (2019 & 2027)
Source: Coherent Market Insights Analysis (2019)
Increasing research and development activities by key players are expected to drive growth of the market over the forecast period
Rising involvement of major players in development of novel, and effective drug candidates for treatment of sexual dysfunction is likely to contribute to the growth of the sexual health market. For instance, in November 2019, Can-Fite BioPharma Ltd. received a patent grant in Canada, South Korea, and Israel for its drug candidate CF602, for the treatment of a sexual dysfunction.
Furthermore, increasing drug approvals from regulatory authorities and product launches are expected to drive the market growth. For instance, in November 2014, Sandoz, the generic pharmaceuticals division of Novartis, launched Vitaros, an innovative topical therapy for erectile dysfunction (ED), in Sweden.
Global Sexual Health Market- Restraints
Number of side effects such as long-lasting erection, facial flushing, visual changes, and hearing loss among others caused by using drugs for treating sexual dysfunctions may hamper consumer demand and growth of the market. Furthermore, increasing cases of undiagnosed or untreated sexual health issues may hinder the market growth.
Global Sexual Health Market- Regional Analysis
Regional segmentation of the global sexual health market includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is estimated to exhibit significant growth in the sexual health market owing to adoption of inorganic growth strategies by key players to launch drugs in the region. For instance, in the fourth quarter of 2015, Valeant Pharmaceuticals International, Inc. acquired Sprout Pharmaceuticals, Inc. In August 2015, Sprout Pharmaceuticals, Inc. received U.S. FDA approval for its New Drug Application (NDA) for flibanserin. Following the acquisition of Sprout Pharmaceuticals, Inc., Valeant Pharmaceuticals has introduced the flibanserin (Addyi) in the U.S. market.
Figure 2: Global Sexual Health Market Share (%), By Region, (2019 & 2027)
Source: Coherent Market Insights Analysis (2019)
Global Sexual health Market- Competitive Landscape
Key players operating in the sexual health market include Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca.
Sexual health is an important part of a person’s physical and mental health. Sexual health leads to the healthy sexual life without any sexual dysfunctions, and preventive measures to avoid sexually transmitted infections. The adult population largely suffers from one or more sexual disorders such as dyspareunia, erectile dysfunctions, hypoactive sexual desire disorder, premature (early) ejaculation, and others. According to National Center for Biotechnology Information 2016, sexual dysfunction is highly prevalent, and affects around 43% of women and 31% of men, globally. Currently, various treatment options such as medication, mechanical aids, sexual therapies, and others are available for treating such sexual dysfunctions and to improve sexual health of the person.
Market Dynamics
Increasing incidence and prevalence of sexual disorders is a major factor augmenting growth of the market. Some of the major factors which cause sexual dysfunction are aging population, stressful and unhealthy lifestyle, and other psychological parameters. According to a study published in the National Center for Biotechnology Information in April 2016, hypoactive sexual desire disorder (HSDD) is present in around 8.9% and 12.3% women in the age group of 18 - 44 years and 45 – 64 years, respectively.
Moreover, robust product development activities by major key players is engaged in the introduction of innovative and highly effective drug treatment for improving sexual health. For instance, in June 2019, AMAG Pharmaceuticals received the U.S. FDA approval for Vyleesi (bremelanotide) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Thus, increasing approvals by regulatory authorities are expected to drive the growth of the sexual health market.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 35 market data tables and 31 figures on "Sexual Health Market” - Global forecast to 2027”.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
